About
Immuno-oncology
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
1,099
By Phase
PHASE3: 2PHASE1: 7
By Status
COMPLETED: 5RECRUITING: 2TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06561048Lead Sponsor
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
PHASE3Recruiting
150 participants
Started: Oct 2, 2024 · Completed: Jul 31, 2028
NCT06345404Lead Sponsor
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
PHASE1Recruiting
72 participants
Started: Apr 23, 2024 · Completed: Nov 30, 2025
NCT04734873Lead Sponsor
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
PHASE3Terminated
46 participants
Started: Feb 25, 2021 · Completed: Aug 18, 2021
NCT04464395Lead Sponsor
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
PHASE1Completed
30 participants
Started: Jul 1, 2020 · Completed: Jul 9, 2021
NCT04280328Lead Sponsor
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
PHASE1Completed
7 participants
Started: Feb 20, 2020 · Completed: Mar 1, 2022
Locations (1)
Headquarters
Burlingame, CA, United States
Map
Loading map...